184 related articles for article (PubMed ID: 22286675)
41. Micafungin use in children.
Emiroglu M
Expert Rev Anti Infect Ther; 2011 Sep; 9(9):821-34. PubMed ID: 21905789
[TBL] [Abstract][Full Text] [Related]
42. In vitro fungicidal activities of anidulafungin, caspofungin, and micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis evaluated by time-kill studies.
Gil-Alonso S; Jauregizar N; Cantón E; Eraso E; Quindós G
Antimicrob Agents Chemother; 2015; 59(6):3615-8. PubMed ID: 25801575
[TBL] [Abstract][Full Text] [Related]
43. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
Heyn K; Tredup A; Salvenmoser S; Müller FM
Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
[TBL] [Abstract][Full Text] [Related]
44. Micafungin - the newest echinocandin.
Temesgen Z; Barreto J; Vento S
Drugs Today (Barc); 2009 Jun; 45(6):469-78. PubMed ID: 19856528
[TBL] [Abstract][Full Text] [Related]
45. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Infect Chemother; 2009 Feb; 15(1):1-5. PubMed ID: 19280292
[TBL] [Abstract][Full Text] [Related]
46. Role of FKS Gene in the Susceptibility of Pathogenic Fungi to Echinocandins.
Hori Y; Shibuya K
Med Mycol J; 2018; 59(2):E31-E40. PubMed ID: 29848909
[TBL] [Abstract][Full Text] [Related]
47. Micafungin: a new echinocandin.
Chandrasekar PH; Sobel JD
Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
[TBL] [Abstract][Full Text] [Related]
48. Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.
Espinel-Ingroff A; Arendrup M; Cantón E; Cordoba S; Dannaoui E; García-Rodríguez J; Gonzalez GM; Govender NP; Martin-Mazuelos E; Lackner M; Lass-Flörl C; Linares Sicilia MJ; Rodriguez-Iglesias MA; Pelaez T; Shields RK; Garcia-Effron G; Guinea J; Sanguinetti M; Turnidge J
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799206
[TBL] [Abstract][Full Text] [Related]
49. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
50. Anidulafungin.
Murdoch D; Plosker GL
Drugs; 2004; 64(19):2249-58; discussion 2259-60. PubMed ID: 15456342
[TBL] [Abstract][Full Text] [Related]
51. The Role of Echinocandins in Candida Biofilm-Related Vascular Catheter Infections: In Vitro and In Vivo Model Systems.
Ghannoum M; Roilides E; Katragkou A; Petraitis V; Walsh TJ
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S618-21. PubMed ID: 26567279
[TBL] [Abstract][Full Text] [Related]
52. [Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-test®].
Thierry G; Morio F; Le Pape P; Gay-Andrieu F; Barre O; Miegeville M
Pathol Biol (Paris); 2011 Feb; 59(1):52-6. PubMed ID: 20832195
[TBL] [Abstract][Full Text] [Related]
53. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
Isham N; Ghannoum MA
J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of amphotericin B and micafungin combination against clinical isolates of Aspergillus species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Chemother; 2011 Apr; 23(2):102-6. PubMed ID: 21571627
[TBL] [Abstract][Full Text] [Related]
55. Albumin Enhances Caspofungin Activity against Aspergillus Species by Facilitating Drug Delivery to Germinating Hyphae.
Ioannou P; Andrianaki A; Akoumianaki T; Kyrmizi I; Albert N; Perlin D; Samonis G; Kontoyiannis DP; Chamilos G
Antimicrob Agents Chemother; 2015 Dec; 60(3):1226-33. PubMed ID: 26643329
[TBL] [Abstract][Full Text] [Related]
56. In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.
Katragkou A; McCarthy M; Meletiadis J; Petraitis V; Moradi PW; Strauss GE; Fouant MM; Kovanda LL; Petraitiene R; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2014 Nov; 58(11):6934-7. PubMed ID: 25136021
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin.
García-Agudo L; García-Martos P; Martos-Cañadas J; Aznar-Marín P; Marín-Casanova P; Rodríguez-Iglesias M
Rev Esp Quimioter; 2012 Dec; 25(4):256-60. PubMed ID: 23303256
[TBL] [Abstract][Full Text] [Related]
58. In vitro combination therapy with isavuconazole against Candida spp.
Katragkou A; McCarthy M; Meletiadis J; Hussain K; Moradi PW; Strauss GE; Myint KL; Zaw MH; Kovanda LL; Petraitiene R; Roilides E; Walsh TJ; Petraitis V
Med Mycol; 2017 Nov; 55(8):859-868. PubMed ID: 28204571
[TBL] [Abstract][Full Text] [Related]
59. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
60. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.
Wagner C; Graninger W; Presterl E; Joukhadar C
Pharmacology; 2006; 78(4):161-77. PubMed ID: 17047411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
